OSR (NASDAQ:OSRH) Stock Price Up 3.4% – Still a Buy?

OSR Holdings, Inc. (NASDAQ:OSRH) shares traded up 3.4% during mid-day trading on Wednesday . The company traded as high as $0.4497 and last traded at $0.4207. 1,870,972 shares changed hands during trading, an increase of 2% from the average session volume of 1,841,323 shares. The stock had previously closed at $0.4068.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the stock. Wall Street Zen upgraded shares of OSR from a “strong sell” rating to a “sell” rating in a research report on Saturday, April 25th. Weiss Ratings restated a “sell (e+)” rating on shares of OSR in a research report on Friday, March 27th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has an average rating of “Sell”.

OSR Stock Up 3.4%

The firm has a market cap of $14.77 million, a PE ratio of -1.27 and a beta of 0.61. The firm’s 50 day moving average is $0.54 and its 200-day moving average is $0.56.

OSR (NASDAQ:OSRH) last released its earnings results on Wednesday, May 13th. The company reported ($0.09) EPS for the quarter. The business had revenue of $0.48 million during the quarter. OSR had a negative net margin of 363.26% and a negative return on equity of 7.24%.

Hedge Funds Weigh In On OSR

A hedge fund recently bought a new stake in OSR stock. Susquehanna International Group LLP purchased a new position in shares of OSR Holdings, Inc. (NASDAQ:OSRH) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 79,807 shares of the company’s stock, valued at approximately $43,000. Susquehanna International Group LLP owned about 0.37% of OSR as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 55.30% of the company’s stock.

About OSR

OSR Holdings leverages its international network of partners in the US, Europe, and South Korea to market and license its pipeline of proprietary platform technologies for broad application to efficient clinical trial programs, with the ultimate goal of addressing unmet medical needs. We partner with biotherapeutics companies with innovative and proprietary drug R&D “platform technologies” versus “assets only” companies, whose commercial viability is heavily dependent on positive results for individual treatment modalities in extremely rigorous and time consuming clinical trials.